Craft
Eliem Therapeutics

Eliem Therapeutics

Market Capitalization

$102.2 M

2023-01-27

Eliem Therapeutics Summary

Company summary

Overview
Eliem Therapeutics is a company developing therapeutics intended to treat neuronal excitability disorders. It offers specialized research and development of drugs for the treatment of chronic pain, depression, epilepsy, and anxiety. The company progresses two clinical-stage assets with mechanisms of action for neurological diseases: ETX-810, an investigational chemical entity (NCE) for chronic pain; ETX-155, an investigational neuroactive steroid NCE that acts as a GABAA positive allosteric modulator (PAM).
Type
Public
Status
Active
Founded
2018
HQ
Redmond, WA, US | view all locations
Website
https://eliemtx.com/
Cybersecurity rating
Sectors

Key people

  • Bob Azelby

    Bob Azelby, President and Chief Executive Officer

  • James Bucher

    James Bucher, Executive Vice President & General Counsel

  • Valerie Morisset

    Valerie Morisset, Executive Vice President, R&D and Chief Scientific Officer

  • Erin Lavelle

    Erin Lavelle, Executive Vice President, Chief Operating Officer & Chief Financial Officer

LocationsView all

2 locations detected

  • Redmond, WA HQ

    United States

    23515 NE Novelty Hill Road, Suite B221

  • Altrincham, England

    United Kingdom

    3rd Floor, 1 Ashley Road

Eliem Therapeutics Financials

Summary financials

Net income (Q3, 2022)
($9.7M)
EBIT (Q3, 2022)
($8.7M)

Footer menu